Title: Reposition of montelukast either alone or in combination with levocetirizine against sars-cov-2

Abstract:

It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), anorher two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV. 

Biography:

Bhattacharyya has completed his Ph. D. at the age of 31yrs from Bose Institute and Jadavpur University, Kolkata, India and Postdoctoral studies from Neurobiotechnology of Ohio State University, USA. He has more than 29 years of research and 5 years of teaching experiences in different University and Institutes. Formerly he was a Protein Biochemist but presently doing research on repurpose of covid medicines as a Principal Investigator from Chichuria Institute of Medical Science and Research, India. He has more than dozon of publication in reputed journals including patents and review. Also discovered and developed some specific natural medicines effective against asthma/SARS, gastritis and pain